Skip to main content

Table 2 Clinical characteristics and outcomes according to IBD-like endoscopic pattern

From: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Characteristic

Crohn’s colitis

N = 39

Ulcerative colitis

N = 76

P value

Duration of symptoms (days, SD)

 IV steroids, n (%)

19 (61.3)

49 (75.4)

0.229

 Infliximab/vedolizumab, n (%)

12 (37.5)

29 (42.0)

0.828

 Duration from onset to recurrence (days, SD)

159 (158)

112 (118)

0.358

 Duration of steroid (days, SD)

70 (117)

60 (43)

0.529

Diarrhea grade, n (%)

  

0.118

 1

5 (12.8)

5 (6.6)

 

 2

145 (35.9)

18 (23.7)

 

 3–4

20 (51.3)

53 (69.7)

 

Colitis grade, n (%)

  

0.201

 1

7 (17.9)

5 (6.6)

 

 2

16 (41.0)

36 (47.4)

 

 3–4

16 (41.0)

35 (46.1)

 

High-risk endoscopic features

23 (59.0)

48 (63.2)

0.689

Active histologic inflammation

33 (84.6)

67 (88.2)

0.574

Outcomes, n (%)

 Hospitalization

30 (76.9)

65 (85.5)

0.301

 Duration of hospitalization (days)

8 (6)

8 (7)

0.855

 ICU admission

2 (5.1)

3 (3.9)

1.000

 Recurrence

15 (38.5)

16 (21.1)

0.074

 Repeat endoscopy

12 (30.8)

15 (19.7)

0.245

  1. Abbreviation: ICU intensive care unit, IV intravenous, SD standard deviation